Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities:
Net loss	$ (75,922)	$ (85,058)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	1,036	878
Stock-based compensation	7,857	7,552
Amortization of debt discount and issuance costs	899	382
Loss on extinguishment of debt	0	7,155
Changes in operating assets and liabilities:
Accounts receivable	(3,881)	(8,435)
Grants and other receivables	0	10
Prepaid expenses and other assets	2,144	(221)
Inventory	(5,773)	2,753
Accounts payable	2,821	(1,928)
Accrued expenses and other liabilities	3,770	4,203
Cash used in operating activities	(67,049)	(72,709)
Investing activities:
Purchases of property and equipment	(460)	(485)
Cash used in investing activities	(460)	(485)
Financing activities:
Proceeds from the sale of common stock	33,600	0
Proceeds from long-term debt	34,447	77,596
Proceeds from the issuance of warrants	0	2,404
Repayment of long-term debt	(4,447)	(80,179)
Cash paid for financing costs	(690)	(3,277)
Proceeds from issuance of common stock under employee stock purchase plan	516	612
Proceeds from the exercise of stock options	76	542
Cash provided by (used in) financing activities	63,502	(2,302)
Effects of exchange rate changes on cash and cash equivalents	(11)	(11)
Net decrease in cash, cash equivalents and restricted cash	(4,018)	(75,507)
Cash, cash equivalents and restricted cash at beginning of period	147,165	201,011
Cash, cash equivalents and restricted cash at end of period	143,147	125,504
Supplemental disclosure of noncash activities:
Fixed asset purchases within accounts payable and accrued expenses	55	17
Financing costs within accounts payable and accrued expenses	147	280
Fair value of common stock issued in connection with Pharmakon amendment	250	0
Recognition of right-of-use assets	5,513	2,479
Recognition of lease liabilities	$ 5,513	$ 2,956